- Home
- XPON vs GLMD Comparison
XPON vs GLMD Comparison
Compare XPON & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPON
- GLMD
- Stock Information
- Founded
- XPON 2016
- GLMD 2000
- Country
- XPON United States
- GLMD Israel
- Employees
- XPON N/A
- GLMD N/A
- Industry
- XPON Electronic Components
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- XPON Technology
- GLMD Health Care
- Exchange
- XPON Nasdaq
- GLMD Nasdaq
- Market Cap
- XPON 2.8M
- GLMD 3.0M
- IPO Year
- XPON 2022
- GLMD 2014
- Fundamental
- Price
- XPON $0.95
- GLMD $1.19
- Analyst Decision
- XPON
- GLMD Hold
- Analyst Count
- XPON 0
- GLMD 1
- Target Price
- XPON N/A
- GLMD N/A
- AVG Volume (30 Days)
- XPON 73.2K
- GLMD 4.8M
- Earning Date
- XPON 05-15-2025
- GLMD 05-29-2025
- Dividend Yield
- XPON N/A
- GLMD N/A
- EPS Growth
- XPON N/A
- GLMD N/A
- EPS
- XPON N/A
- GLMD N/A
- Revenue
- XPON $5,624,939.00
- GLMD N/A
- Revenue This Year
- XPON $61.26
- GLMD N/A
- Revenue Next Year
- XPON N/A
- GLMD N/A
- P/E Ratio
- XPON N/A
- GLMD N/A
- Revenue Growth
- XPON N/A
- GLMD N/A
- 52 Week Low
- XPON $0.67
- GLMD $1.21
- 52 Week High
- XPON $223.00
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- XPON 51.33
- GLMD 38.80
- Support Level
- XPON $0.93
- GLMD $1.16
- Resistance Level
- XPON $1.12
- GLMD $1.33
- Average True Range (ATR)
- XPON 0.08
- GLMD 0.14
- MACD
- XPON 0.01
- GLMD 0.00
- Stochastic Oscillator
- XPON 42.18
- GLMD 7.41
About XPON Expion360 Inc.
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.